Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03869086
Other study ID # AMP001_22NOV2018
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 4, 2019
Est. completion date January 6, 2021

Study information

Verified date January 2021
Source University of East Anglia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to find out if consuming a single dose of blueberries, rich in anthocyanins, within an energy dense meal, improves blood vessel function and biomarkers of heart health. The study specifically aims to confirm if differences in how individuals process the bioactive compounds in blueberries, called anthocyanins, has an influence on heart health. The investigators will assess the effects of eating one portion of blueberries on vascular health over a 48hour period, and will track the breakdown compounds within blood and urine, to see if health effects are related to metabolism.


Description:

The primary aim of this cross-over designed, placebo controlled, acute dietary intervention study, is to prospectively recruit participants on the basis of anthocyanin metabolism profiles (based on profiles confirmed in our previous studies) following a 'blueberry challenge'. Acute cardio and metabolic function responses will be assessed (by metaboliser profile), following an energy dense test meal with/without the addition of blueberries. Participants will be healthy, but overweight and obese (BMI inclusion: ≥ 25kg/m2) men and women (aged 50 y to 80 y), who will initially undertake a 'blueberry challenge' by consuming a single dose of freeze dried blueberries. Anthocyanin metaboliser type will be profiled from the analysis of metabolites within urine, collected for 48h following the 'challenge'. A total of 70 participants will complete the intervention (n=35 FAST and n=35 SLOW metabolisers) which consists of two, test meal periods (separated by at least 7d and allocated in random order); 1) energy dense test meal plus freeze dried blueberries, 2) energy dense test meal plus an isocaloric matched placebo material. Urine samples and ambulatory blood pressure measures will be collected for 24h prior to, and then over the 48h period which follows the test meal intake. Further assessment of vascular and metabolic function will be made at pre-defined times over the 48h postprandial period. Dietary restrictions to abstain from blueberries and reduce the anthocyanin intake level, will be applied for 5d before each test meal intake. In addition, all food and drink will be provided for a 4d period (2d before and during the 48h following the energy dense test meal) to further control the intake of flavonoids and to standardise the influence of background diet on metabolism profile.


Recruitment information / eligibility

Status Terminated
Enrollment 49
Est. completion date January 6, 2021
Est. primary completion date January 6, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: - BMI >= 25 kg/m2 - Adults aged 50 - 80 years old - Successful biochemical, haematological, and urinalysis assessment at screening Exclusion Criteria: - Current smokers, or ex-smokers ceasing < 6 months ago - existing or significant past medical history of vascular disease or medical conditions likely to affect the study measures - Fructose or lactose intolerant subjects or known allergies to intervention treatments - Those unprepared to adhere to dietary instructions - Parallel participation in another research project involving dietary intervention and/or sampling of biological fluids/material - Those on therapeutic diets or having experienced substantial weight loss within 2 months of screening. - Those taking flavonoid, nitrate / nitrite containing or fish oil containing supplements (and unwilling to cease intake during, and 1 month preceding the trial) or unwilling to maintain existing intake of other supplements. - Prescribed hypoglycaemic, anti-hypertensive, vasodilator or hormone replacement therapy (HRT) medication. - Unsatisfactory biochemical, haematological or urinary results or measurements considered to be counter indicative for the study - Undiagnosed hypertension (elicited at screening; i.e. = 180 / 110mmHg) at a level requiring immediate referral back to general practitioner for follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Freeze dried blueberry powder
36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
Anthocyanin free, sugar-matched placebo
36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.

Locations

Country Name City State
United Kingdom Quadram Institute Clinical Research Facility; a partnership facility of the NHS, UEA and QIB Norwich Norfolk

Sponsors (1)

Lead Sponsor Collaborator
University of East Anglia

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Microbiome assessment of phyla and species Assessment of the gut microbiome from faecal samples collected from FAST and SLOW anthocyanin metabolisers. Sample collected up to 2 days prior to test meal 1 and assessed within 5 years of study completion
Other Ambulatory blood pressure Measurement of pre-intervention and postprandial ambulatory blood pressure 1 day before, and the two days following the intake of each energy dense test meal
Other Aortic arterial stiffness (cf-PWV) Measurement of carotid to femoral pulse wave velocity assessed at 0, 3, 6, 24, 48 hours after intervention intake
Other Systemic arterial stiffness (AIx) Measurement of brachial augmentation index (adjusted to 75 beats per minute heart rate) assessed at 0, 3, 6, 24, 48 hours after intervention intake
Other Bioavailability - urine Assessment of flavonoid and metabolite levels in 24 hour urine samples 3 days during the blueberry challenge (1 day before and the two days of the assessment) and 3 days during each test meal assessment (1 day before and the two days of the assessment)
Other Postprandial glucose response Assessment of postprandial glucsoe control Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
Other High density lipoprotein cholesterol Assessment of blood high density lipoprotein cholesterol Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
Other Triglycerides Assessment of blood triglycerides Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
Other Low density lipoprotein cholesterol Assessment of blood low density lipoprotein cholesterol Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
Primary Brachial artery endothelial function percentage maximum dilatation assessed via flow mediated dilation (%FMD): (diametermax-diameterbaseline) / diameterbaseline×100. assessed at 0, 1.5, 3, 6, 24, 48 hours after intervention intake
Secondary Office blood pressure Measurements of blood pressure Assessed at 0, 3, 6, 24, 48 hours after intervention intake.
Secondary Bioavailability - serum Assessment of flavonoid and metabolite levels in blood samples Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
Secondary Postprandial Insulin response Assessment of postprandial insulin control Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
Secondary Total cholesterol Assessment of blood cholesterol Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1